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ABSTRACT The insulin-like growth factors IGF-I and
IGF-ll circulate in blood bound to carrier proteins. The higher
molecular mass IGF-binding protein complex (150 kDa) is
composed of subunits, and one subunit that forms this complex
is growth hormone dependent. In addition, many cell types and
tissues secrete another form of IGF binding protein that is not
growth hormone dependent. Both forms of the IGF binding
protein are believed to inactivate the IGFs and to function as
delivery systems to tissues. This conclusion was based on
studies that determined the effects of impure preparations of
these binding proteins or that examined the effect of these
proteins only on the insulin-like actions of the IGFs. We report
here that a pure preparation of the extracellular form of the
IGF binding protein (purified from human amniotic fluid)
markedly potentiated replication of several cell types in re-
sponse to human IGF-I. Secondary cultures of human, mouse,
and chicken embryo fibroblasts as well as porcine aortic smooth
muscle cells showed marked enhancement of their DNA syn-
thesis response (2.8- to 4.4-fold increases) to IGF-I in the
presence of this protein. These responses were synergistic since
the sum of the responses to either IGF-I or to the binding
protein alone was between 8 and 17% of the increase obtained
in cultures exposed to both peptides. The binding protein not
only potentiated the DNA synthesis response but also enhanced
the increase in cell number in response to IGF-I. This stimu-
lation is specific for growth factors that bind to the binding
protein since incubation with insulin, which binds to the type
I IGF receptor but not to the binding protein, did not result in
potentiation of this response. We conclude that a form of IGF
binding protein that is present in extracellular flulids and is
secreted by many types of cells can markedly potentiate the
cellular response to IGF-I.
Human insulin-like growth factor I (IGF-I), also termed
somatomedin C, is a growth hormone dependent growth
factor that circulates in blood (1) and is synthesized in many
tissues (2). Like other growth factors, such as epidermal
growth factor, that circulate in plasma, the IGFs are bound
to a binding protein that forms a 150-kDa carrier protein-
IGF-I complex and is believed to serve a transport function.
Partially purified forms of this protein have been shown to
inhibit the insulin-like actions of IGF-I (3). An acid-stable
binding subunit of this complex has been purified from blood,
and its secretion can be stimulated by growth hormone (4, 5).
In contrast, extracellular fluids such as spinal (6), lymph (7),
and amniotic (8) as well as tissue extracts from brain (9) and
pituitary (9) contain a form of IGF binding protein that has a
different molecular mass and is not growth hormone depen-
dent. It binds both IGF-I and IGF-II with affinities in the
1010-109 M-1 range. This protein has been shown to be
secreted by some cell types in culture including human
fibroblasts (10). This binding protein has been purified to
homogeneity from human amniotic fluid and has molecular
mass estimates between 32 and 38 kDa (8, 11). Impure
preparations of this protein, or a similar protein that is
secreted by rat liver cells, have been shown to inhibit the
effects of IGF-I and IGF-II on fibroblast DNA synthesis (12)
or on sulfate incorporation into cartilage (8), presumably by
preventing the binding of IGF-I to its cell surface receptor.
However, recent studies have shown that if this protein is
adherent to cell surfaces it causes an increase in the amount
of IGF-I that binds to the IGF receptor and to cell surfaces
(10). These studies were undertaken, therefore, to determine
the effect of a pure preparation of the IGF-I binding protein
on IGF-I stimulated DNA synthesis in several types of cells
in culture.
MATERIALS AND METHODS
Cell Culture Techniques. Porcine aortic smooth muscle
cells were isolated by a previously described method (13).
Stock cultures were plated at 8000 cells per cm2 in 10-cm
plastic dishes (Falcon Labware Division, Becton Dickinson,
Oxnard, CA; 3001). They were maintained in Dulbecco's
modified Eagle's medium (DMEM) (GIBCO) that was sup-
plemented with 10% fetal bovine serum (FBS) (HyClone,
Ogden, UT). They were passaged every 10-12 days by
removing the cells with 0.03% trypsin/0.02% EDTA
(GIBCO) and replating at a 1:5 dilution. All experiments were
conducted using cells between the fourth and seventh pas-
sages. Individual experiments were conducted using cultures
that had been plated at 8000 cells per well in 96-well microtest
plates (Falcon 3004) in 0.2 ml ofDMEM supplemented with
10% FBS and had been grown for 5 days. At that time the
serum-containing medium was removed, and test substances
were added to 0.2 ml of DMEM supplemented with 1%
human platelet poor plasma (PPP) and 0.5 uCi (1 Ci = 37
GBq) of [3H]thymidine (15 Ci/mmol) (Schwartz/Mann).
Control wells received DMEM containing either 1% PPP or
various concentrations of human serum (1-10%). The PPP
and serum were prepared using a previously described
method (13). The PPP was determined by RIA (13) to contain
<20 pg of platelet factor 4 per ml. Following a 36-hr incubation,
the reaction was stopped and the amount of [3H]thymidine that
had been incorporated into DNA was determined (13).
Chicken embryo fibroblasts, which were a gift of John
Olsen (Univ. of North Carolina), were isolated from 14-16
day chicken embryo skin. The primary explants were plated
in medium 199 (GIBCO) supplemented with 4% FBS
(HyClone), 10% chicken serum, penicillin (100 units/ml), and
streptomycin (100 gg/ml) (GIBCO). The cells that grew from
Abbreviations: PPP, platelet-poor plasma; FBS, fetal bovine serum;
DMEM, Dulbecco's modified Eagle's medium; MEM, minimum
essential medium; IGF, insulin-like growth factor.
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the explants were passaged one time and then were subcul-
tured on 96-well plates (Falcon 3004) at 3000 cells per well in
DMEM supplemented with 10%o FBS. After five days, the
monolayers were washed and test factors were added with
0.2 ml ofDMEM containing 0.5 ,tCi of [3H]thymidine and 1%
PPP; then [3Hjthymidine incorporation was determined after
a 36-hr incubation as described previously. Mouse embryo
fibroblasts were obtained from 18-day fetal BALB/c mouse
(skin) and were grown in DMEM/10% FBS/10 mM gluta-
mine (Sigma)/penicillin (100 units/ml)/streptomycin (100
Ag/ml). Cultures between the third and fifth passages were
used for all experiments.
Human fibroblasts were purchased from the Human Mu-
tant Genetic Cell Respository (Camden, NJ). They were
maintained in stock cultures in Eagle's minimum essential
medium (MEM) (GIBCO) supplemented with penicillin (100
units/ml), streptomycin (100 ,tg/ml), and 10%6 bovine serum
(Colorado Serum, Denver, CO). They were passaged every
7 days using a passage dilution ratio of 1:4. Cultures between
the fourth and fifth passages were plated at a density of 8000
cells per well on microtest plates for use in individual
experiments. After 5 days, the cultures were washed twice
with MEM then with 0.2 ml ofMEM containing 1% PPP; 0.5
,uCi of [3H]thymidine and test substances were added, and
[3H]thymidine incorporation was determined after 36 hr as
described previously.
To determine if the binding protein could potentiate the cell
growth response to IGF-I, human fibroblasts or smooth
muscle cells were plated at densities of 15,000 cells per cm2
in 24-well plates (Falcon 3003) containing 1.0 ml of DMEM
plus 10% FBS (smooth muscle) or MEM plus 10%6 calf serum
(fibroblasts). After 2 hr, to allow for cell attachment, the
media were aspirated and 1.0 ml of media containing 1% PPP
was added. After a 12-hr incubation to allow the cells to
become quiescent, the media were removed and replaced
with 1.0 ml of MEM containing 1% PPP and the test
substances. After 48 hr of incubation, the cultures were
exposed to 1.0 ml of0.5% trypsin/0.03% EDTA for 10 min at
37°C. This was removed and added to 9.0 ml of 0.15 mM
NaCl, and the cell number was determined using a particle
data counter (Coulter, Model ZBI).
Purification of Growth Factors. Human IGF-I was pur-
chased from Amgen Biologicals (Thousand Oaks, CA).
Porcine insulin (lot PJ5682) was a gift from Eli Lilly. The IGF
binding protein was purified by a modification of a previously
published method (11). The modified procedure substituted
DEAE-cellulose chromatography as the second purification
step. The peak that eluted with 100 mM NaCl was further
purified by reverse-phase HPLC (C4 column). The purifica-
tion was monitored using a specific assay that measures IGF
binding capacity (10). Ten microliters of each column fraction
was incubated with 40,000 cpm of "2-I-labeled IGF-I (150
,uCi/,ug) (14) for 60 min at 22°C in 0.1 M Hepes (Sigma)/0.1%
bovine serum albumin (Sigma)/0.1% Triton X-100/44 mM
NaCO3/0.02% NaN3, pH 6.0(250 ,ul volume). Bound and free
1251-labeled IGF-I were separated by adding 1% immune
serum globulin and 500 ,ul of 25% polyethylene glycol (Mr,
8000). The mixture was centrifuged at 8000 x g for 10 min,
and the pellet was washed with 6.25% polyethylene glycol.
The final product was pure as determined by polyacrylamide
gel electrophoresis using silver staining and by amino acid
sequence analysis (15).
RESULTS
The binding protein that had been purified from human
amniotic fluid was incubated with quiescent porcine aortic
smooth muscle cell cultures. This cell type was chosen
because it does not have IGF binding protein that is adherent
to its cell surface (10). Addition of the IGF-I binding protein
alone resulted in minimal stimulation of [3H]thymidine in-
corporation (Fig. LA). Addition of IGF-I (20 ng/ml) or insulin
(10 jig/ml) resulted in only 15 and 38% increases in [3H]thy-
midine incorporation, respectively (Fig. lA). In contrast,
addition of IGF-I (20 ng/ml) plus the pure binding protein
(100 ng/ml) resulted in a 4.4-fold stimulation (compared to
binding protein alone), a potentiation that exceeded the
cellular response to 10% human serum. At concentrations of
10 ,ug/ml, insulin binds to the type I IGF receptor but not to
the binding protein (10). When these concentrations ofinsulin
were added with the binding protein, there was no potenti-
ation of the cellular replication response, indicating that
activation ofthe binding protein effect was specific for IGF-I.
To determine if cell types from different species might
respond to the IGF-I binding protein in a similar manner, the
effect of this protein plus IGF-I was tested using chicken and
mouse embryo fibroblast cultures. These cell types were
chosen because the chicken cells do not synthesize an IGF
binding protein, but they do possess type I IGF receptors.
The mouse cells secrete a different form of IGF binding
protein (-22 kDa), and neither cell type has IGF binding
protein on their cell surfaces. Addition of pure IGF binding
protein resulted in only minimal changes in [3H]thymidine
incorporation in either cell type (Fig. 1 B and C). In contrast,
the binding protein at 100 ng/ml plus IGF-I showed marked
potentiation of the cellular response to IGF-I. The chicken
fibroblasts were particularly sensitive; 81% of the maximal
response induced by 10% human serum was reached with
only 5 ng of IGF-I per ml (Fig. 1B). The mouse fibroblasts
were also sensitive to the effects of the coincubation of IGF
binding protein and IGF-I (Fig. 1C). Neither cell type
responded to insulin plus IGF binding protein, indicating that
the binding protein-IGF-I complex had to be formed to
achieve the maximal stimulation of [3H]thymidine incorpo-
ration.
To determine if human fibroblasts, a cell type that synthe-
sizes the IGF binding protein, could also respond to exoge-
nously added peptide, quiescent human fibroblast cultures
were prepared as described in Fig. 2. Addition of increasing
concentrations of IGF-I resulted in an increase in [3H]thy-
midine uptake into DNA that was maximal at 20 ng/ml and
was 82% greater than control cultures that were exposed to
1% PPP alone. The enhanced response to IGF-I alone
compared to chicken or mouse fibroblasts may have been due
to endogenously secreted IGF-I binding protein. Addition of
the IGF binding protein alone resulted in no increase in DNA
synthesis. However, when this protein (100 ng/ml) was
added with increasing concentrations of IGF-I, DNA syn-
thesis was augmented to a level that was equal to that
obtained when 10% human serum was added. In separate
studies, we have determined that these cells synthesize and
secrete the IGF binding protein into media (16) and that this
protein can attach to the cell surface (10). However, fibro-
blasts only secrete sufficient binding protein to reach media
concentrations of 2-5 ng/ml, and since 100 ng/ml was added
to these cultures, this difference probably accounts for the
additional increase in [3H]thymidine incorporation that was
present.
To determine if these responses were dependent upon the
concentration of the binding protein, increasing concentra-
tions of binding protein (1-100 ng/ml) plus a constant
concentration of IGF-I (10 ng/ml) were incubated with
smooth muscle cell cultures. The cultures responded to
binding protein at 2 ng/ml with a significant increase in
[3H]thymidine incorporation, but a maximal effect was not
obtained until 100 ng/ml was used (Fig. 3). Since cultured
fibroblasts secrete concentrations of IGF binding protein in
the range of 2-5 ng/ml, this result indicates that the fibro-
blasts probably were not secreting a quantity of binding
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FIG. 1. Potentiation of DNA synthesis in porcine aortic smooth
muscle cells and also chicken and mouse embryo fibroblasts by IGF-I
and the IGF binding protein. (A) Smooth muscle cells were subcultured
on 96-well microtest plates at a plating density of8000 cells per well, and
5 days were allowed for the cells to become quiescent. Prior to the
analysis, the cultures were washed twice with serum-free DMEM; then
test substances were added in 0.2 ml ofDMEM supplemented with 0.5
jLCi of [3H]thymidine and 1% PPP. (B) Chicken embryo fibroblasts
(second passage) were subcultured on 96-well microtest plates (Falcon
3004) at a plating density of3000 cells per well in DMEM supplemented
with 10%1 FBS. Five days after plating, the quiescent monolayers were
exposed to the test factors listed plus 0.5 ILCi of [3H]thymidine per ml
and 1% PPP. (C) Mouse embryo fibroblast cultures between the third
and fifth passages were used, and the experiments were performed as
described for the chicken embryo fibroblasts except that the cells were
plated at 8000 cells per well. Cultures were exposed to increasing
concentrations ofhuman serum (u-u, curves 1), insulin (A-A, curves
2), IGF-I (- *, curves 3), IGF-I plus binding protein at 100 ng/ml
(e-_, curves 4), or insulin and binding protein at 100 ng/ml (A---A,
curves 5) for 36 hr, and [3H]thymidine incorporation was quantitated
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FIG. 2. Stimulation ofDNA synthesis by the IGF binding protein
in cultured human fibroblasts. Cells between the fourth and eighth
passages were subcultured in 96-well microtest plates in MEM
supplemented with 10% calf serum at a density of 8000 cells per well.
Five days after plating, the cultures were washed with serum-free
MEM; then 0.2 ml ofMEM containing 0.5 ,Ci of [3H]thymidine, 1%
PPP, and the stated concentrations of test substances were added.
Increasing concentrations of human serum (u u, curve 1), IGF-I
(a*-, curve 2), insulin (A-,, curve 3), IGF-I plus binding protein
at 100 ng/ml (a--e, curve 4), or insulin plus binding protein at 100
ng/ml (A---A, curve 5) were added to quiescent human fibroblast
monolayers, and after a 36-hr incubation, DNA synthesis was
determined. Results are expressed as means of triplicate cultures.
protein sufficient to achieve a maximal DNA synthesis
response.
To determine if cells that were stimulated by IGF-I plus the
binding protein could traverse the full cell cycle, smooth
muscle cells and human fibroblasts were plated at a low
density and made quiescent by serum deprivation. After 12
hr, the binding protein and IGF-I or insulin were added to test
cultures, and the fibroblasts were incubated for 48 hr before
the cell number was determined. Addition of IGF-I or insulin
alone resulted in 3 and 11% increases in smooth muscle cell
number, whereas the binding protein plus IGF-I (10 ng/ml)
effected a 2.4-fold increase. This increase was greater than
that induced by 10% human serum (Fig. 4A). Similar results
were obtained with human fibroblasts, but the effect of IGF-I
alone was greater (Fig. 4B). IGF-I alone resulted in a 31%
increase, whereas the combination of binding protein plus
IGF-I gave a 2.1-fold increase in cell number after 48 hr.
DISCUSSION
These results indicate that the addition of the IGF-I binding
protein to cells exposed to IGF-I markedly facilitates the cell
growth response of smooth muscle cells and fibroblasts to
this growth factor. This response is specific for IGF-I since
the combination of insulin with this protein did not result in
enhancement of the growth response to this factor. Since the
response to IGF-I plus binding protein is much greater than
to IGF-I or binding protein alone, this suggests that the
complex of both proteins is required for maximal growth
stimulation. This requirement could provide a mechanism for
tissue specific stimulation of growth by IGF-I since the
presence of the binding protein in the microenvironment
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achieved by altering IGF-I degradation or by increasing its
binding to the type I receptor.
Our laboratory has previously shown that human fibro-
-fA-2 blasts synthesize and secrete an IGF binding protein that can
be specifically immunoprecipitated by an antibody to the
human amniotic fluid protein. Following its synthesis, the
fibroblast protein interacts with the cell surface, and its
presence on the cell surface is associated with an increase in
cell-associated IGF-I (10). Addition of increasing concentra-
tions of IGF-I results in increased cell association of IGF-I
due to enhanced binding to both cell surface binding protein
and the type I IGF receptor. Inhibition of synthesis of the
binding protein by coinqubation with cycloheximide com-
pletely eliminates this enhanced association ofIGF-I with the
cell surface. The above data support the concept that there is
an interaction between the cell surface concentration of the
binding protein and enhancement of IGF-I binding to both its
receptor and the binding protein. This enhancement of IGF-I
binding could be directly related to the marked augmentation
in DNA synthesis that is induced by' the IGF-I-binding
protein complex as noted in these studies. It is possible that
this increase in the amount ofIGF-I that is associated with the
cell surface and the concomitant increase in binding to the
type I receptor activate a major cellular growth response to
smooth muscle IGF-I and that under these conditions mesenchymal cell
Cultures were growth is partially independent of the usual requirements for
Im (A---A, curve other mitogens, such as platelet-derived growth factor or
3F-I (10 ng/ml) epidermal growth factor.
ldetermined as These findings suggest that cell types that secrete this
[3H]thymidine binding protein might be able to augment their response to
IGF-I in an autocrine or paracrine manner. Control of
synthesis and secretion of the protein could function as a
and cell types mechanism to control cell proliferation in the microenviron-
to respond to ment and to locally modulate the response to IGF-I even at
IGF binding a time when blood and extracellular fluid concentrations of
i, as has been this growth factor remained constant. Although plasma
There to cell concentrations of the binding protein have been shown to be
facilitate the age and estrogen dependent (17), control of its secretion by













FIG. 4. Growth of cultured fibroblasts and smooth muscle cells in response to IGF-I and the IGF binding protein. Porcine smooth muscle
cells (A) and human fibroblasts (B) were plated at 15,000 cells per well on 24-well plates (Falcon 3004) in MEM plus 10% calf serum (fibroblasts)
orDMEM plus 10o fetal calf serum (smooth muscle cells). After 2 hr, the media were changed toMEM orDMEM containing 1% PPP. Following
an additional 12-hr incubation, the media were removed and test reagents were added to 0.5 ml ofDMEM orMEM containing 1% PPP. Following
a 48-hr incubation, cell number was determined. The results are expressed as the mean ± 1 SD of quadruplicate cultures. B3ars: 1, 1% PPP; 2,
10% human serum; 3, binding protein (100 ng/ml); 4, IGF-I (10 ng/ml); 5, insulin (10 pg/ml); 6, binding protein (100 ng/ml) plus IGF-I (10 ng/ml);
7, binding protein (100 ng/ml) plus insulin (10 tg/ml).
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previously that exposure of BALB/c 3T3 fibroblasts to
platelet-derived growth factor can induce an increase in
IGF-I binding to the cell surface (14). Since this change could
have been due to an increase in the amount of IGF binding
protein that was present, we have measured the cell surface
concentration of the binding protein after exposure to plate-
let-derived growth factor. We found, however, that its level
on the fibroblast surface was not increased by exposure to
platelet-derived growth factor or epidermal growth factor
(D.R.C., M. Dehoff, and S. L. S. Drop, unpublished results).
Recently Rutanen et al. demonstrated that progesterone
increases the IGF binding protein synthesis in human
decidual tissue explants (18). It is possible, therefore, that
local synthesis and release of the IGF binding protein may be
under hormonal regulation in specific tissues.
The exact mechanism by which the binding protein-IGF-I
complex activates DNA synthesis was not addressed by
these studies. It is possible that the complex associates
directly with the membrane to activate transmembrane signal
mechanisms or that it can activate these processes only in
cooperation with the type I receptor. Alternatively, the
IGF-I-binding protein complex might be directly internalized
and act at an intracellular site. Regardless of the mechanism
of transmembrane signaling, it is possible that this complex
could induce the synthesis of a specific growth regulatory
protein. Recently the type 8 transforming growth factor has
been shown to induce c-sis and c-myc expression in AKR-2B
cells in culture (19). Since many growth regulatory proteins
are believed to control early events in cell cycle progression,
it will be of interest to determine if this complex can enhance
their expression.
Other growth factors have been shown to associate with
binding proteins (20, 21) either during secretion or transport
in plasma; however, none of the other growth factor binding
proteins have been shown to augment the cellular growth
response to these mitogens. Since many of the binding
proteins may not have been tested, however, this possibility
has not been rigorously excluded. During the purification of
the IGF binding protein, we noted that impure material
inhibited the growth response to IGF-I, and it was only when
material was obtained in pure form that its stimulatory
activity was noted. Our observation that a pure form of this
protein is required to detect this biologic response may help
to explain data of others showing that similar IGF binding
proteins purified from plasma or cellular conditioned media
inhibit IGF action. Zapf et al. (3) found that an impure
preparation of the IGF binding protein purified from plasma
inhibited insulin-like actions of IGF-I. Likewise Drop et al.
(8), by using impure human amniotic fluid protein, showed
inhibition of cartilage sulfation by IGF-I. A possible expla-
nation for this difference between pure and impure prepara-
tions of the IGF-binding protein has been provided by our
recent observation that human amniotic fluid contains two
forms of the binding protein and that one form inhibits
IGF-I-stimulated DNA synthesis (15). Knauer and Smith
have used a homogeneous preparation ofrat liver cell-derived
IGF binding protein, however, and have found it to inhibit
DNA synthesis in chicken embryo fibroblasts (12). This
species difference may be important since the rat protein
does not crossreact with antibody to the human protein and
has a distinct amino terminal sequence (11, 22). Our labora-
tory has noted that the rat form of the binding protein does
not associate with the chicken embryo or human fibroblast
cell surfaces, and this observation supports the hypothesis
that cell surface association may be required for the biologic
response noted herein.
The presence of an alternative mechanism for activating
cell growth suggests possible approaches to the analysis of
pathophysiologic conditions. Many types of dwarfism are
associated with normal blood IGF-I concentrations, but they
might be due to a deficiency of the IGF binding protein (23).
Likewise, some syndromes such as Beckwith-Weideman
(24) that are associated with macrosomia but normal IGF-I
concentrations could be due to a generalized increased
synthesis of this protein. Of greater interest is the possibility
that local synthesis of this protein by fibroblasts or other cell
types could augment the local response to IGF-I. This could
occur in response to injuries, such as wounding or athero-
sclerosis, where a localized proliferative response occurs but
is confined to a small area. By this mechanism, the cells that
are secreting increased concentrations of the binding protein
could divide in the presence of normal ambient IGF-I levels
while surrounding tissues that are exposed to equal IGF-I
concentrations might be less sensitive to its effects.
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